Methylprednisolone and cortisol metabolism during the early post-renal transplant period.
Despite the widespread use of methylprednisolone and the well-appreciated effects of this drug on HPA suppression, little data is available which describes individual patient exposure to both methylprednisolone and cortisol following renal allograft placement. The clinical utilization of methylprednisolone during the early post-transplant period is based upon standardized dosing protocols that do not consider factors which may influence the pharmacokinetics of this drug during the post-transplant period. Therefore, this study was designed to examine the pharmacokinetics of methylprednisolone (mean dose: 28 mg) and cortisol pharmacodynamics in 9 renal transplant recipients (4 females; 5 males) who were studied during the early post-transplant period (5 to 12 days after surgery). All patients (mean serum creatinine: 1.4 +/- 0.3 mg/dl) had serial blood samples collected over a 12- to 24-hour period (depending upon the dosing schedule) which were analyzed concurrently for methylprednisolone and cortisol. A three-fold variation in drug clearance ranging from 174 to 638 ml/h/kg with a range in the volume of distribution of 0.83 to 2.24 l/kg and resultant half-lives ranging from 1.20 to 3.02 hours was noted. The cortisol response was quantitated by a 12-hour cortisol area under the curve (C-AUC12) to examine the interpatient cortisol patterns during the early post-transplant period. C-AUC12 ranged from 44.0 to 636 ng.h/ml. Significant correlations were noted between the cortisol plasma concentration at 12 hours and methylprednisolone clearance and area under the concentration versus time curve (AUC). Interpatient variability in the disposition of methylprednisolone and cortisol response noted during the early post-transplant period contradict the clinical assumptions which underlie the fixed dosing protocols currently utilized for methylprednisolone.
Tornatore
K M
KM
Department of Pharmacy Practice, School of Pharmacy, State University of New York at Buffalo, USA.
Reed
K A
KA
Venuto
R C
RC
D000328:Adult; D005260:Female; D005938:Glucocorticoids / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D008775:Methylprednisolone / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008875:Middle Aged; D013997:Time Factors
D005938:Glucocorticoids; D006854:Hydrocortisone; D008775:Methylprednisolone